Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 2,951 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 2,951 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $228.95, for a total transaction of $675,631.45. Following the transaction, the insider owned 123,499 shares of the company’s stock, valued at $28,275,096.05. This represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total transaction of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total transaction of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total value of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $193,858.56.
• On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The shares were sold at an average price of $187.95, for a total value of $54,881.40.

Natera Stock Up 4.8%

Shares of NASDAQ NTRA traded up $11.32 during midday trading on Tuesday, hitting $248.74. The stock had a trading volume of 1,550,717 shares, compared to its average volume of 965,766. The stock has a 50 day simple moving average of $224.18 and a 200-day simple moving average of $184.78. The company has a market capitalization of $34.41 billion, a PE ratio of -108.62 and a beta of 1.62. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $249.15.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.26) earnings per share. As a group, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently made changes to their positions in the stock. Hilltop National Bank acquired a new position in shares of Natera during the second quarter worth about $33,000. Horizon Investments LLC purchased a new position in Natera in the third quarter worth approximately $32,000. Oliver Lagore Vanvalin Investment Group purchased a new position in Natera in the second quarter worth approximately $36,000. Sound Income Strategies LLC grew its holdings in Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several research reports. BNP Paribas raised shares of Natera to a “hold” rating and set a $172.00 price objective for the company in a research note on Monday, October 27th. Stephens increased their price target on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Morgan Stanley lifted their price objective on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Evercore ISI upped their target price on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, UBS Group raised their target price on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Fifteen equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $235.29.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.